SANA

Sana Biotechnology, Inc. (SANA) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Sana Biotechnology is a clinical-stage biotechnology company focused on developing engineered cell therapies for Type 1 diabetes, oncology, and autoimmune diseases. The company operates two primary platforms: an ex vivo hypoimmune platform (HIP) and an in vivo fusogen platform. As of the reporting date, the company has no approved products and has incurred net losses since inception.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $2.0 million (4.0%) to $48.6 million. This reduction was driven by a $8.5 million decrease in core Research and Development (R&D) expenses, primarily due to lower personnel costs and reduced third-party manufacturing costs following the suspension of two allogeneic CAR T programs (SC291 and SC262) in November 2025.
• Contingent Consideration: R&D-related success payments and contingent consideration expenses increased significantly by $6.5 million to $8.4 million. This was primarily due to a $10.7 million expense related to the revaluation of Cobalt Contingent Consideration, partially offset by gains on success payment liabilities.
• Liquidity: Cash and marketable securities decreased by approximately $37.2 million compared to the prior year period, reflecting ongoing operational burn despite a net cash increase of $11.9 million during the quarter due to investing activities (maturities of marketable securities).

Guidance, Outlook, and Risks

• Going Concern: Management has determined that current capital resources may not be sufficient to fund planned operations for at least one year from the filing date. There is substantial doubt as to the company's ability to continue as a going concern without additional financing.
• Strategic Prioritization: The company is focusing resources on SC451 (Type 1 diabetes) and SG293 (in vivo CAR T for B-cell malignancies/autoimmune diseases). Development of SC291 and SC262 has been suspended.
• Financing Activities:
  • In March 2026, the company entered into an amended At-The-Market (ATM) sales agreement allowing for the sale of up to $150.0 million of common stock.
  • In April 2026 (subsequent event), the company entered into a stock purchase agreement with Mayo Clinic to sell up to 15 million shares for gross proceeds of up to $50.0 million.
• Risks: Key risks include the need for additional capital, the uncertainty of clinical trial outcomes, regulatory hurdles for novel cell therapies, and significant contingent liabilities (up to $500 million for Cobalt milestones and $175 million for Harvard success payments) that fluctuate based on stock price and market capitalization.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $101.1 million cash balance against the stated "substantial doubt" regarding the ability to fund operations for the next 12 months.
• Contingent Liabilities: Review the fair value assumptions for the $134.5 million Cobalt Contingent Consideration and $16.9 million success payment liabilities, as these are highly sensitive to stock price volatility.
• Subsequent Financing: Confirm the closing status and terms of the April 2026 stock purchase agreement with Mayo Clinic.
• Program Status: Monitor progress on the IND filing for SC451 and preclinical data readouts for SG293, which are the primary drivers of future value.
• Legal Proceedings: Track the status of the pending securities class action litigation filed in March 2025 regarding statements about the SC291 program.